Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia

Abstract

BackgroundImatinib mesylate has revolutionized the treatment of chronic myeloid leukemia leading to significant reductions of BCR-ABL1 transcript levels in peripheral blood.ObjectiveTo evaluate the response to imatinib mesylate treatment (400 mg/day) in Brazilian patients in the chronic phase of chronic myeloid leukemia monitored by quantitative real time polymerase chain reaction.MethodsBetween October 2002 and October 2010, 3169 peripheral blood samples were collected from 1403 patients from 3 to 5 months, 6 to 11 months, 12 to 17 months, 18 to 23 months and ≥24 months after beginning imatinib treatment. Eighty-two patients had samples available and analyzed for all time intervals. BCR-ABL1 quantification was performed by quantitative real time polymerase chain reaction using the ABL1 gene as the control. Results of the BCR-ABL1 ratio as a percentage were reported by the international scale (IS) using the laboratory conversion factor (0.51).ResultsIn the first interval, 80.8% of patients achieved the optimal response (BCR-ABL1IS ≤ 10%). In the second period, 69.1% achieved optimal response (BCR-ABL1IS ≤ 1%) and, between 12 and 17 months, 47.3% achieved major molecular response (BCR-ABL1IS ≤ 0.1%).ConclusionsThe results of this retrospective study show that the response to imatinib treatment (400 mg/day) of Brazilian patients in the chronic phase of chronic myeloid leukemia is within the expected profile when compared to patients reported in international prospective randomized studies.

Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia

“…31 Furthermore, the results of our study are comparable with the 63.4% MMR that was achieved between months 18 and 23 of therapy in the study of 1403 patients on imatinib from Brazil. 32 There was no significant correlation between MMR achievement status and 84-month OS rates. However, achievement of MMR at month 24 was significantly correlated with a higher probability of 84-month PFS rates (97.9% vs. 85.5%; P < .0001).…”

Análise de mutações do domínio BCR-ABL quinase em pacientes com leucemia mielóide crônica refratários ao tratamento com mesilato de imatinibe

“…Sobre o intervalo entre o diagnóstico e o início do tratamento, 69% dos pacientes iniciaram o tratamento em menos de 1 ano. Estudos recentes descrevem uma maior probabilidade de melhores respostas moleculares quando o tratamento é iniciado previamente 23 . Assim, levantamos a hipótese de que, mesmo com uma intervenção medicamentosa rápida, a não adesão à terapia pode resultar em falha terapêutica.…”

Distribution of BCR–ABL1 Transcript Variants in Nigerians with Chronic Myeloid Leukemia

“…Significant progress has been made in the management of CML with the discovery and subsequent approval of Imatinib, the first of a class of drugs that specifically inhibit tyrosine kinases (called tyrosine kinase inhibitors or TKIs) and block their effects on cellular proliferation of malignant clones [2,12]. Imatinib produces significantly favorable clinical, hematologic, cytogenetic and molecular responses in CML patients [12,13]. Most patients improve with Imatinib but some do not, either due to Imatinibintolerance or resistance [2,14].…”